SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 36,241 Shares of Company Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 36,241 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $24.80, for a total value of $898,776.80. Following the completion of the sale, the senior vice president directly owned 40,167 shares of the company’s stock, valued at $996,141.60. The trade was a 47.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Stock Down 0.1%

SIBN stock traded down $0.03 during trading on Friday, reaching $24.24. 683,472 shares of the stock were exchanged, compared to its average volume of 638,581. The firm’s 50 day moving average is $19.71 and its 200 day moving average is $16.56. The firm has a market cap of $1.09 billion, a P/E ratio of -78.19 and a beta of 0.64. The company has a current ratio of 7.58, a quick ratio of 7.55 and a debt-to-equity ratio of 0.19. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The firm had revenue of $55.70 million during the quarter, compared to analysts’ expectations of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. As a group, research analysts forecast that SiBone will post -0.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on SIBN. TD Cowen upped their price objective on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup reiterated a “market outperform” rating on shares of SiBone in a report on Tuesday. UBS Group boosted their target price on shares of SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Finally, Truist Financial raised their price target on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, SiBone has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Trading of SiBone

Several institutional investors have recently made changes to their positions in the company. D.A. Davidson & CO. raised its holdings in shares of SiBone by 2.8% in the third quarter. D.A. Davidson & CO. now owns 37,814 shares of the company’s stock valued at $711,000 after purchasing an additional 1,038 shares during the last quarter. First Light Asset Management LLC boosted its holdings in SiBone by 51.8% during the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock worth $132,649,000 after purchasing an additional 2,774,795 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in SiBone by 40.3% during the second quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock worth $1,928,000 after purchasing an additional 33,947 shares during the last quarter. VELA Investment Management LLC boosted its holdings in SiBone by 7.4% during the second quarter. VELA Investment Management LLC now owns 201,094 shares of the company’s stock worth $3,282,000 after purchasing an additional 13,934 shares during the last quarter. Finally, Corient Private Wealth LP grew its position in SiBone by 119.6% in the 2nd quarter. Corient Private Wealth LP now owns 43,946 shares of the company’s stock worth $717,000 after purchasing an additional 23,938 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.